Georgiamune Inc. logo

Georgiamune Inc.

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseases.

30 employees · est. 2014 · Gaithersburg, United States

VS
ImmunoGenesis, Inc. logo

ImmunoGenesis, Inc.

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.

14 employees · est. 2019 · Houston, United States

Georgiamune Inc. is the older company (2014 vs 2019).

Side-by-Side Comparison

Georgiamune Inc. ImmunoGenesis, Inc.
Founded
2014 older 2019
Headquarters
Gaithersburg, United States Houston, United States
Employees
30 14
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Health and Wellness
Funding Stage
Series A Series Unknown
Total Funding
$75.00M $28.00M
Funding Rounds
2 4
Services
Reprogramming Immune Responses, Drug Design and Development, Preclinical Research, Pipeline Development Not tracked yet
Target Customers
Healthcare Providers, Oncologists, Immunologists, Patients with Cancer, Patients with Autoimmune Diseases, Biopharmaceutical Companies Not tracked yet
Taxonomy
Immunotherapy, Immune Signaling Pathways, Clinical Stage, Cancer Treatment, Autoimmune Diseases, Immune Therapeutics, Scientific Discovery, Reprogramming Immune System, Disease Fighting, Immune Balance, Biopharmaceuticals Immuno-oncology, Biopharmaceutical, Drug Development, Immune Resistance, Immune-excluded Tumors, Immunotherapy, Clinical-stage, Immune Response, Tumor Pathology, Cancer Treatment, Immune System, Therapy Development
Website
georgiamune.com immunogenesis.com
Georgiamune Inc. logo

About Georgiamune Inc.

Georgiamune Inc., founded in 2014, operates at the intersection of biotechnology, health care, and wellness. This U.S.-based clinical-stage immunotherapeutic biotechnology firm is driving innovation by reprogramming immune signaling pathways, a strategy aimed at redefining immune system responses to...

ImmunoGenesis, Inc. logo

About ImmunoGenesis, Inc.

ImmunoGenesis, Inc. is a clinical-stage immuno-oncology biopharmaceutical company focused on re-envisioning the treatment of "cold" tumors, particularly immune-excluded tumors. These tumors, which account for over half of all cancers, are resistant to current immunotherapies due to mechanisms that s...

We will tell you when either one moves

BounceWatch watches Georgiamune Inc. and ImmunoGenesis, Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Georgiamune Inc. and ImmunoGenesis, Inc. — by email.

Frequently Asked Questions

Georgiamune Inc. — Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseases.. ImmunoGenesis, Inc. — Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of immune resistance.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Georgiamune Inc. has raised $75.00M while ImmunoGenesis, Inc. has raised $28.00M.
Georgiamune Inc. and ImmunoGenesis, Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Georgiamune Inc. with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Georgiamune Inc. on 9 Jun 2026, and ImmunoGenesis, Inc. on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy